Papers, abstracts, presentations, posters and webcasts emanating from the audit
EASD 2021: Crabtree, T. S. J., K. Adamson, H. Reid, D. Barnes, S. Sivappriyan, A. Bickerton, I. W. Gallen, and R. E. J. Ryder. "The use of semaglutide alongside other diabetes medications: real-world results from the Association of British Clinical Diabetologists (ABCD) audit programme." In DIABETOLOGIA, vol. 64, no. SUPPL 1, pp. 236-237. ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES: SPRINGER, 2021. https://youtu.be/f6_bMVyFWjw
Thomas SJ Crabtree, Karen Adamason, Alex Bickerton, Alison Evans, Suzanne Phillips, Alison Gallagher, Niels Larsen, Dennis Barnes, Ketan Dhatariya, Benjamin CT Field, Iskaner Idris, Robert EJ Ryder, on behalf of all ABCD semaglutide audit contributors. The factors predicting glucose and weight response to injectable semaglutide (Ozempic):real-world data from the Association of British Clinical Diabetologists’ audit programme. The British Journal of Diabetes, Volume 23 Issue 2 / December 2023
DOI: https://doi.org/10.15277/bjd.2023.418
Crabtree, T. S. J., K. Adamson, H. Reid, D. Barnes, S. Sivappriyan, A. Bickerton, I. W. Gallen, B. C. T. Field, I. Idris, and R. E. J. Ryder. "Injectable semaglutide and reductions in HbA1c and weight in the real‐world in people switched from alternative glucagon‐like peptide 1 receptor agonists." Diabetes, Obesity and Metabolism (2022). https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14701
All contributors are listed
EASD 2022 Semaglutide 1st and 2nd Oral Slides
Thomas S.J. Crabtree, Devesh K. Sennik, Alex Bickerton, Dennis Barnes, Siva Sivappriyan, Karen Adamson, Suzanne M. Phillips, Alison Evans, Niels Larsen, Avinash Panesar, Melissa L. Cull, Ian W. Gallen, Iskandar R. Idris, Robert E. Ryder. 756-P: The Effect of Semaglutide on Alanine Aminotransferase (ALT) Levels: Results from the Association of British Clinical Diabetologists (ABCD) Audit. Diabetes 2022;71(Supplement_1):756-P DOI: https://doi.org/10.2337/db22-756-P
T. S. J. Crabtree, K. Adamson, H. Reid, D. Barnes, S. Sivappriyan, A. Bickerton, I. W. Gallen, A. Gallagher, I. Idris, R. E. J. Ryder. Predictors of HbA1c and weight response to semaglutide: Results from the Association of British Clinical Diabetologists (ABCD) audit programme. Diabetic Medicine, Volume 39, Issue S1:A56 (P231)
Oral Abstract: https://onlinelibrary.wiley.com/doi/10.1111/dme.14809
Poster Abstract: https://onlinelibrary.wiley.com/doi/10.1111/dme.14810
T. S. J. Crabtree, K. Adamson, H. Reid, D. Barnes, S. Sivappriyan, A. Bickerton, I. W. Gallen, and R. E. J. Ryder. "The use of semaglutide alongside other diabetes medications: real-world results from the Association of British Clinical Diabetologists (ABCD) audit programme." In DIABETOLOGIA, vol. 64, no. SUPPL 1, pp. 236-237. ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES: SPRINGER, 2021.
ADA June 2022
EASD 2022
DUK Professional Conference March 2022
ADA June 2021
ABCD Virtual Meeting December 2020
The ABCD nationwide semaglutide audit is an independent audit supported by an unrestricted grant from Novo Nordisk
